823 related articles for article (PubMed ID: 28577748)
1. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
2. [Membranous nephropathy: Pathophysiology and natural history].
Seitz-Polski B; Lambeau G; Esnault V
Nephrol Ther; 2017 Apr; 13 Suppl 1():S75-S81. PubMed ID: 28577747
[TBL] [Abstract][Full Text] [Related]
3. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I
Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972
[TBL] [Abstract][Full Text] [Related]
4. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
[TBL] [Abstract][Full Text] [Related]
5. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
[TBL] [Abstract][Full Text] [Related]
6. Primary membranous nephropathy: comprehensive review and historical perspective.
Keri KC; Blumenthal S; Kulkarni V; Beck L; Chongkrairatanakul T
Postgrad Med J; 2019 Jan; 95(1119):23-31. PubMed ID: 30683678
[TBL] [Abstract][Full Text] [Related]
7. [Membranous nephropathy: Diagnosis, new insights in pathophysiology, and therapeutic approach].
Dahan K
Rev Med Interne; 2016 Oct; 37(10):674-679. PubMed ID: 27236434
[TBL] [Abstract][Full Text] [Related]
8. Primary Membranous Nephropathy.
Couser WG
Clin J Am Soc Nephrol; 2017 Jun; 12(6):983-997. PubMed ID: 28550082
[TBL] [Abstract][Full Text] [Related]
9. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
[No Abstract] [Full Text] [Related]
10. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
[TBL] [Abstract][Full Text] [Related]
12. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
Front Immunol; 2021; 12():738788. PubMed ID: 34721403
[TBL] [Abstract][Full Text] [Related]
13. Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy.
Timmermans SA; Abdul Hamid MA; Cohen Tervaert JW; Damoiseaux JG; van Paassen P;
Am J Nephrol; 2015; 42(1):70-7. PubMed ID: 26344651
[TBL] [Abstract][Full Text] [Related]
14. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
[TBL] [Abstract][Full Text] [Related]
15. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological treatment of primary membranous nephropathy in 2016.
van de Logt AE; Hofstra JM; Wetzels JF
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1463-1478. PubMed ID: 27535699
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
Kumar V; Ramachandran R; Kumar A; Nada R; Suri D; Gupta A; Kohli HS; Gupta KL; Jha V
Nephrology (Carlton); 2015 Aug; 20(8):572-5. PubMed ID: 26194981
[TBL] [Abstract][Full Text] [Related]
18. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
Ishiwatari A; Wakai S; Shirakawa H; Honda K
Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
[TBL] [Abstract][Full Text] [Related]
19. Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Ruetsch C; Graça D; Esnault VLM; Brglez V; Seitz-Polski B
Front Immunol; 2022; 13():859419. PubMed ID: 35603210
[TBL] [Abstract][Full Text] [Related]
20. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
Guerry MJ; Vanhille P; Ronco P; Debiec H
Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
[No Abstract] [Full Text] [Related]
[Next] [New Search]
